Scarica l'app Stockscreener
5.73
0.70%
0.04
Dopo l'orario di chiusura:
5.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.69
Aprire:
$5.72
Volume 24 ore:
184.87K
Relative Volume:
0.97
Capitalizzazione di mercato:
$308.75M
Reddito:
-
Utile/perdita netta:
$-35.10M
Rapporto P/E:
-8.1265
EPS:
-0.7051
Flusso di cassa netto:
$-31.49M
1 W Prestazione:
+7.50%
1M Prestazione:
-5.45%
6M Prestazione:
-30.21%
1 anno Prestazione:
+60.50%
Intervallo 1D:
$5.635
$5.95
Intervallo di 1 settimana:
$5.245
$5.95
Portata 52W:
$3.475
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Nome
Diamedica Therapeutics Inc
Settore
Industria
Telefono
(763) 496-5454
Indirizzo
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
5.73 | 303.36M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-30 | Iniziato | TD Cowen | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-06-22 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Iniziato | Oppenheimer | Outperform |
| 2021-02-17 | Iniziato | ROTH Capital | Buy |
| 2020-10-30 | Iniziato | Guggenheim | Buy |
| 2020-07-08 | Iniziato | Maxim Group | Buy |
| 2019-04-30 | Iniziato | Dougherty & Company | Buy |
| 2019-03-05 | Iniziato | Lake Street | Buy |
Mostra tutto
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
DiaMedica Therapeutics (DMAC) Gains 3.66% as Biotech Stock Tests Key Resistance ZonePut Spread Alert - newsline.com
DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84 - Stock Titan
DiaMedica (DMAC) director Richard Kuntz receives grant of 40,412 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) director granted 40,412-share stock option award - Stock Titan
DiaMedica (DMAC) director Tanya Lewis awarded 40,412 stock options at $5.84 - Stock Titan
DiaMedica Therapeutics (DMAC) director receives 40,412-share stock option grant - Stock Titan
DiaMedica Therapeutics (NASDAQ: DMAC) director receives grant of 51,189 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CEO awarded 380,000 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CFO awarded 162,000 stock options at $5.84 strike - Stock Titan
DiaMedica Therapeutics (DMAC) CMO receives 67,500 stock options expiring 2036 - Stock Titan
DiaMedica Shares Down Ahead of Stroke Trial Update - Bez Kabli
DiaMedica (DMAC) Q4 2025 Earnings Transcript - The Globe and Mail
DiaMedica Therapeutics (DMAC) Slides 2.76% as Biotech Sector Headwinds Pressure Small-Cap NamesWave Equality - The Legal Advocate
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - BioSpace
DMAC Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline AdvancesProfit Guidance Range - The Legal Advocate
DiaMedica Therapeutics (DMAC) Gains 4% as Stock Approaches Key Resistance LevelCumulative Volume - The Legal Advocate
DiaMedica Therapeutics (DMAC) Gains 2.43% as Buyers Defend Key SupportSynthetic Long - The Legal Advocate
DiaMedica Shareholders Approve Governance, Compensation and Incentive Plan - The Globe and Mail
DMAC Q1 2026 Earnings: Wider Loss Than Expected as Clinical Pipeline AdvancesFinancial Health Score - thelegaladvocate.com
DiaMedica Therapeutics (NASDAQ: DMAC) investors approve directors, pay and 3.5M-share incentive plan boost - Stock Titan
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - BioSpace
DiaMedica stroke trial reaches 75% of interim analysis threshold By Investing.com - Investing.com South Africa
DiaMedica stroke trial reaches 75% of interim analysis threshold - Investing.com India
DiaMedica Therapeutics (DMAC) Advances in Pivotal Trial Enrollme - GuruFocus
DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment - marketscreener.com
Diamedica Therapeutics announces 75% enrollment milestone in Remedy2 phase 2/3 acute ischemic stroke trial - marketscreener.com
Why Is DiaMedica Therapeutics Inc. (DMAC) Stock Down Today? - Meyka
TradingKey - TradingKey
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
MSN Money - MSN
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2026 Earnings Call Transcript - insidermonkey.com
DiaMedica (DMAC) Q1 2026 Earnings Transcript - AOL.com
Why DiaMedica (DMAC) deserves a deeper look right now (Bearish Sentiment) 2026-05-08Social Investment Platform - newser.com
DiaMedica Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : DiaMedica Therapeutics Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
DiaMedica Therapeutics Q1 Earnings Call Highlights - Barchart.com
DiaMedica Therapeutics Inc. Q1 2026 Financial Results, Clinical Trial Updates, and Forward-Looking Statements - Minichart
Earnings call transcript: DiaMedica Therapeutics Q1 2026 results show R&D focus - Investing.com
DMAC: DM199 trials progress in preeclampsia and stroke, with strong cash position and key data ahead - TradingView
Diamedica Therapeutics Inc. (DMAC) Files Form 8-K with Financial Statements and Company Information for May 2026 - Minichart
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience - ChartMill
[10-Q] DiaMedica Therapeutics Inc. Quarterly Earnings Report - Stock Titan
DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Higher R&D drives DiaMedica (NASDAQ: DMAC) wider Q1 2026 loss - Stock Titan
Diamedica Therapeutics Inc Azioni (DMAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Diamedica Therapeutics Inc Azioni (DMAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
| STAHLBERG JAN | 10% Owner |
Aug 25 '25 |
Buy |
6.00 |
338,265 |
2,029,252 |
7,654,045 |
| STAHLBERG JAN | 10% Owner |
Aug 13 '25 |
Buy |
5.91 |
293,601 |
1,734,918 |
7,058,066 |
| STAHLBERG JAN | 10% Owner |
Aug 14 '25 |
Buy |
5.99 |
70,414 |
421,921 |
7,128,480 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):